Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Andrey Lev-Weissberg

Internal Medicine Park Ridge, IL Medical Doctor

NPI 1245206655 CMS profile 147248

1775 Dempster St, Park Ridge, IL 60068

Open in the dashboard

General payments

$9,295

426 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Andrey Lev-Weissberg of Park Ridge, IL is reported in the CMS Open Payments database as having received $9,295 across 426 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,448 53
2024 General $1,329 49
2023 General $1,154 49
2022 General $1,364 64
2021 General $1,419 70
2020 General $1,015 58
2019 General $1,567 83

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Andrey Lev-Weissberg
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Andrey Lev-Weissberg were reported at $1,448. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Andrey Lev-Weissberg Internal Medicine median Middle half National median
2019 $1,567 $159 $48–$570 $163
2020 $1,015 $119 $33–$402 $114
2021 $1,419 $135 $37–$521 $132
2022 $1,364 $141 $42–$496 $149
2023 $1,154 $149 $45–$519 $160
2024 $1,329 $154 $47–$537 $164
2025 $1,448 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,206 75 payments
  2. AbbVie, Inc. $1,146 55 payments
  3. Otsuka America Pharmaceutical, Inc. $876 24 payments
  4. Lilly USA, LLC $684 35 payments
  5. Lundbeck LLC $486 22 payments
  6. Bayer HealthCare Pharmaceuticals Inc. $460 19 payments
  7. Pfizer Inc. $446 20 payments
  8. Amgen Inc. $355 16 payments
  9. Novartis Pharmaceuticals Corporation $342 18 payments
  10. Salix Pharmaceuticals, a division of Bausch Health US, LLC $333 19 payments
  11. Other $2,961 123 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,136 420 payments
  2. Education $159 6 payments
Products named General payments · program years 2019–2025
  1. VRAYLAR $894 41 payments
  2. Ozempic $884 53 payments
  3. REXULTI Psychiatry $865 23 payments
  4. RYBELSUS $668 36 payments
  5. REXULTI Psychiatry $486 22 payments
  6. Kerendia $460 19 payments
  7. TRULICITY $436 23 payments
  8. ELIQUIS $344 12 payments
  9. XIFAXAN $309 18 payments
  10. ENTRESTO $298 16 payments
  11. Other $5,675 270 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 200 drugs

Part D claims

11,893

Median for Internal Medicine: 777

Drug cost

$1,079,938

Median for Internal Medicine: $73,373

Branded share of claims

20.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 436 $195,211
Ingrezza Valbenazine Tosylate Brand 20 $152,572
Ozempic Semaglutide Brand 71 $97,232
Rexulti Brexpiprazole Brand 19 $42,444
Jardiance Empagliflozin Brand 71 $41,276
Xarelto Rivaroxaban Brand 77 $41,122
Zenpep Lipase/Protease/Amylase Brand 17 $40,803
Linzess Linaclotide Brand 58 $38,039
Januvia Sitagliptin Phosphate Brand 30 $26,486
Combivent Respimat Ipratropium/Albuterol Sulfate Brand 27 $20,681

The 10 drugs with the highest cost, of 200 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$296,150

Medicare's payments for the services billed

Medicare patients

356

Average age 77

Services billed

3,260

204 women, 152 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 64%
Heart failure 57%
Diabetes 56%
Ischemic heart disease 47%
Depression 45%
Chronic kidney disease 41%
Atrial fibrillation 36%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Otsuka America Pharmaceutical, Inc. $199
  • Lundbeck LLC $103
$302 19 —
VRAYLAR
  • AbbVie, Inc. $229
$229 — —
MOUNJARO
  • Lilly USA, LLC $104
$104 — —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $70
$70 — —
SPRAVATO
  • Janssen Pharmaceuticals, Inc $62
$62 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

426 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record